Physician profile
David B Staub
NPI 1255319422
$3,394.54
in general payments reported to CMS, 2019-2025
25 companies · $720 in 2025
The $720 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $205 · 2021: $333 · 2022: $343 · 2023: $479 · 2024: $722 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.36 |
| Education | $228.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $584.75 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $569.23 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $395.53 | 2019-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.44 | 2019-2024 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $186.60 | 2019-2025 | |
| Ucb, INC. | $182.33 | 2019-2025 | Bimzelx, Cimzia |
| Teva Pharmaceuticals USA, INC. | $129.22 | 2023-2024 | Truxima |
| Pfizer INC. | $118.23 | 2019-2024 | |
| Glaxosmithkline, LLC. | $95.56 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $93.76 | 2019-2023 | Taltz |
| Organon LLC | $89.01 | 2022-2025 | Hadlima |
| Radius Health, INC. | $88.73 | 2019-2024 | Tymlos |
| Mckesson Specialty Care Distribution, LLC | $81.43 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $67.71 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $62.02 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $61.38 | 2019-2023 | |
| Genentech USA, INC. | $57.58 | 2019-2025 | Gazyva |
| E.R. Squibb & Sons, L.L.C. | $55.30 | 2019-2025 | Orencia |
| Almatica Pharma LLC | $28.98 | 2025 | Teriparatide |
| Celgene Corporation | $26.11 | 2019 | |
| Janssen Scientific Affairs, LLC | $25.10 | 2021 | |
| Aurinia Pharma U.S., INC. | $21.34 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $18.74 | 2019 | |
| Merck Sharp & Dohme LLC | $14.02 | 2020 | |
| Sandoz INC. | $13.44 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Staub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.